Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: April 2019 (Specifically April 10, 2019)
The filing serves to disclose a material corporate event regarding the Company's clinical development program. It incorporates by reference a press release issued on April 10, 2019.
Key Financial Metrics
This filing is a current report of a specific event and does not contain financial statements, revenue figures, profit data, cash flow information, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial indicators.
Material Changes
The primary material change disclosed is the acceptance of a late-breaking abstract for oral presentation at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO). The abstract details results from a recently completed multicenter Phase II trial in patients with advanced liver cancer.
Outlook, Risks, and Management Commentary
Management Commentary: The Company highlighted the significance of the Phase II trial results being selected for a late-breaking abstract session at ASCO, indicating potential clinical relevance.
Risks and Contingencies: No specific risks or contingencies are detailed in this specific Form 6-K text, though clinical trial outcomes inherently carry development risks.
Unusual Items: The acceptance of the abstract for oral presentation is the notable unusual item driving this filing.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for specific clinical data points and trial endpoints.
- Confirm the date and location of the ASCO 54th Annual Meeting presentation.
- Review subsequent filings for the actual presentation outcomes and any regulatory feedback following the ASCO announcement.
- Check the Company's latest Form 20-F for updated financial status and cash runway, as this filing contains no financial data.